CRISPR-Edited TILs Fight Advanced Colorectal Cancer in Patients

Although immunotherapeutic strategies have made huge strides in treatment for solid tumors, the promising results have not moved over into the treatment of gastrointestinal cancer. Now, a first-in-human clinical trial shows encouraging signs of safety and potential effectiveness of a CRISPR/Cas9 gene-editing technique to help TILs fight advanced colorectal cancer.